SAVE THE DATES & REGISTRATION

Hosted by The Global HIV Vaccine Enterprise in partnership with the HIV Vaccine Trials Network, the HIV Prevention Trials Network and and the Forum for Collaborative Research

Registration for Session 3 now open !

Workshop Home Session 3

IF YOU HAVE ALREADY ATTENDED SESSION 1 AND 2 YOU DO NOT NEED TO REGISTER AGAIN,

YOU WILL RECEIVE THE ZOOM REGISTRATION BY EMAIL.

If you are attending for the first time, please register below to get your personal Zoom link on the next page!

Future Trial Design Approaches 2020 - Workshop Series

Session 3 online events

Name*
First Last
Location*
Country
Occupation*
Affiliation*
Email*
Enter Email Confirm Email
Did you attend any of the 2020 panel discussion?*
- Yes
- No
Consent to Privacy Policy*
When you visit our website some personal information may be collected by the IAS. We will only use such information for the purposes of (i) administering certain programmes as identified to you at the time of collection, (ii) a form where the information is no longer identifiable with you, for statistical and marketing analyses and (iii) registration to on of the conference for which IAS is an organizer or co-organizer.

The IAS is committed to protecting your privacy and takes its responsibilities regarding the security of your information very seriously. The IAS requires certain information to allow your registration. The IAS collects the details provided by you, together with information it learns about you form your use of IAS service and your visits to IAS websites and other sites accessible from them. The IAS also collects information about the transactions you undertake including details of payment cards used. The IAS will also use your contact details to communicate with you.

The information that you provide to the IAS will be held in the IAS systems, which are located on our premises or those of an appointed third party. The IAS may also allow access to your information by other third parties who act for the IAS, namely for the purposes of registration, accommodation, travel and for abstract submission. Should the IAS consider possible to disclose some of your information to third parties beyond the scope of purposes stated above, you will be notified before giving such information to the IAS.

In using an IAS website, you consent to the collection and use of this information in the ways described above. Should you have any question in relations to this privacy policy, please contact us at info@iasociety.org.

If the IAS decides to change its Privacy Policy, those changes will be mentioned on this page so that you are always aware of what information is collected, how the IAS uses it and in what circumstances such information may be disclosed.
I agree to the privacy policy.
Phone
This field is for validation purposes and should be left unchanged.

Workshop Home Session 1 Session 2 Session 3

HIV prevention is evolving rapidly with the roll out of new tools such as pre-exposure prophylaxis (PrEP) and treatment as prevention making a significant contribution towards controlling the epidemic. As a result, the design and conduct of the next generation of prevention trials is impacted and is further affected by the outcomes of ongoing HIV prevention efficacy trials – including oral and injectable antiretrovirals, passively infused monoclonal antibodies, and HIV vaccines.

This series of virtual workshop aims to continue from the first HIV Prevention Efficacy Trial Designs of the Future symposium, held in November 2018 in Seattle by the Fred Hutch and the NIAID, which led to a series of articles published in Statistical Communications in Infectious Diseases and a viewpoint in The Lancet HIV.

Participants will reflect on more recent advances and challenges within the HIV prevention field and on the rationale and lessons learned for current HIV prevention designs. They will examine novel scientific approaches for establishing efficacy of new biologics in a future where all trial participants have access to effective prevention.

The event will feature a series of online talks given by biostatisticians and clinical trial experts, and will include live panel discussions with clinicians, ethicists, regulators, community members and sponsors.

The programme is designed to accommodate virtual interactions and will offer pre-recorded presentations available online on-demand and live events focused on discussion.

A series of articles, based on the talks given at the symposium, will be published in a selected high-impact journal.

Please share among your network.

More details on each session will be sent out closer to the date.

Date	Event
27 October 2020	Live session 1: Current efficacy trial design approaches – Challenges and lessons learned
Friday 6 November	Live session 2A: Future design approaches for settings where all participants are on active prevention – ARV based prevention
Wednesday 18 November	Live session 2B: Future design approaches for settings where all participants are on active prevention – Vaccines
25 February 2021	Live Session 3A: Novel Scientific Approaches for Establishing Efficacy of New Biologics
March 2021	Live session 2C: Future design approaches for settings where all participants are on active prevention – Monoclonal antibodies
April 2021	Panel Discussion 3B: Community engagement and involvement in clinical research Regulatory forum organized by the Forum for Collaborative research

Organizing Committee

Holly Prudden, International AIDS Society, Geneva, Switzerland.
Holly Janes, Fred Hutchinson Cancer Research Center, Seattle, USA.
Deborah Donnell, Fred Hutchinson Cancer Research Center, Seattle, USA.
Stephaun Wallace, Fred Hutchinson Cancer Research Center, Seattle, USA.
Veronica Miller, Forum for Collaborative Research, Berkeley, USA.
Roger Tatoud, International AIDS Society, Geneva, Switzerland.
Linda-Gail Bekker. Desmond Tutu HIV Centre, University of Cape Town (UCT), South Africa.

For queries, please contact enterprise@iasociety.org.

The organization of this workshop is supported by a grant from the Bill and Melinda Gates Foundation and the US National Institutes of Health (NIH).

Design Approaches for Current and Future HIV Prevention Efficacy Trials

SAVE THE DATES & REGISTRATION

Registration for Session 3 now open !

Future Trial Design Approaches 2020 - Workshop Series

Organizing Committee

About

Global HIV Vaccine Enterprise

Contact Us